Opus Genetics (IRD) Equity Ratio (2010 - 2026)

Opus Genetics (IRD) has 17 years of Equity Ratio data on file, last reported at 0.69 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.69, down 751.63% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.69 (down 751.63% YoY), and the FY2025 annual result was 0.31, up 67.47% from the prior year.
• Equity Ratio declined to 0.69 in Q1 2026 per IRD's latest filing, from 0.31 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.94 in Q4 2022 and troughed at 0.69 in Q1 2026.
• A 5-year average of 0.6 and a median of 0.84 in 2022 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2025 and 2026: Equity Ratio surged 67.47% in 2025, then slumped 751.63% in 2026.
• A 5-year view of Equity Ratio shows it stood at 0.94 in 2022, then decreased by 1.98% to 0.93 in 2023, then sank by 80.28% to 0.18 in 2024, then surged by 67.47% to 0.31 in 2025, then slumped by 324.67% to 0.69 in 2026.
• Business Quant data shows IRD's Equity Ratio at 0.69 in Q1 2026, 0.31 in Q4 2025, and 0.17 in Q3 2025.